

## Curriculum Vitae Kiem Dian Liem, M.D.

---

### **Business Address:**

Pacific Shores Medical Group  
1043 Elm Avenue, Suite #104  
Long Beach, CA 90813  
Phone: (562) 590-0345  
Fax: (562) 437-8139

### **Professional Accreditation**

July 2016	Assistant Clinical Professor of Medicine University of California, Los Angeles, School of Medicine
Oct 2013	Recertification, Internal Medicine, Diplomat American Board of Internal Medicine (157574)
July 2009	Clinical Instructor University of California, Los Angeles, School of Medicine
Sep 2007	Recertification, Medical Oncology, Diplomat American Board of Internal Medicine (157574)
Sep 2007	Recertification, Hematology, Diplomat American Board of Internal Medicine (157574)
May 2004	Recertification, Internal Medicine, Diplomat American Board of Internal Medicine (157574)
Aug 1997	Hematology, Diplomat, American Board of Internal Medicine (157574)
Aug 1997	Medical Oncology Diplomat, American Board of Internal Medicine
Aug 1994	Internal Medicine, Diplomat American Board of Internal Medicine
July 1991	Educational Commission for Foreign Medical Graduates (457-327-5)
Jun 1991	Federal Licensing Examination (610225010)
Apr 1987	M.D., Radboud University Nijmegen, The Netherlands
Mar 1985	M.Sc. Medicine, Radboud University Nijmegen, The Netherlands

### **Postgraduate Training**

July 1994-July 1997	Hematology & Oncology Fellowship Program University of California, Irvine Medical Center, Orange, California
July 1991-July 1994	Internal Medicine Residency Program University of Connecticut Health Center, Farmington, Connecticut
Feb 1990-Sep 1990	Emergency Medicine Senior House Officer Charing Cross Hospital, London, United Kingdom.
Aug 1989-Jan 1990	Internal Medicine Internship Luton & Dunstable Hospital, Luton, United Kingdom
Aug 1988-Jan 1989	Surgical Internship (General Surgery & Urology) St. Mary's Hospital, Portsmouth, United Kingdom

### **Positions**

Aug 2013- present	Medical Director Anticoagulation Center, Greater Newport Physicians
July 2009- 2014	Tumor Board Chair, St. Mary Medical Center, Long Beach, CA
Jan 2009- present	IT and EMR Director, Pacific Shores Medical Group
July 2004- Present	Director of Clinical Research Program, Pacific Shores Medical Group

## **Curriculum Vitae** **Kiem Dian Liem, M.D.**

---

Sep 1999- present Pacific Shores Medical Group, Medical Oncology Practice  
Sep 1997-Sep 1999 Coast Hematology Oncology Associates, Long Beach, California  
Medical Oncology Practice  
May 1996-Sep 1997 Sunrise Medical Group, Orange, California  
Urgent Care Clinic  
Feb 1989-July 1989 Locum tenens in Internal Medicine and Surgery, United Kingdom

### **Hospital Affiliations**

St. Mary Medical Center, Long Beach, California  
Long Beach Memorial Medical Center, Long Beach, California  
Los Alamitos Medical Center, Los Alamitos, California  
Hoag Memorial Hospital Presbyterian, Newport Beach/Irvine, California  
Orange Coast Memorial Medical Center, Fountain Valley, California  
College Medical Center Long Beach, Long Beach, California

### **Clinical Research**

Jan 1996–Jun 1996 Moloney Murine Leukemia Virus Ribozyme  
University of California at Irvine, California  
Nov 1987–Dec 1987 Parasited Erythrocytes and Immunogenic Parasited Erthrocytes in  
Plasmodium bergei.  
Radboud University Nijmegen, The Netherlands  
Aug 1987–Sep 1987 Characterization of Glutamate Dehydrogenase and Ammonia in  
Bacillus fastidiosus  
Radboud University Nijmegen, The Netherlands  
Oct 1985–Dec 1985 T-cell receptor rearrangements in Mycosis Fungoides and Sézary  
Syndrome.  
British Columbia Cancer Research Centre, Vancouver, British  
Columbia, Canada

### **Professional Development**

Sep 1993-Oct 1993 Adult and Pediatric Bone Marrow Transplant Unit  
Fred Hutchinson Cancer Research Center, Seattle, Washington  
Jun 1987-Jun 1988 Medical Biology  
Radboud University Nijmegen, The Netherlands  
• Accredited in applied statistics, immunology, computer programming,  
clinical and immuno-toxicology

### **Publications**

June 2015 SYK & PI3K $\delta$  pathway inhibition resulted in increased rates of  
pneumonitis: Implications for developing future small molecule  
combinations.  
P M Barr , G Saylor , S Spurgeon, B Cheson, D Greenwald, S  
O'Brien, A Liem, R McIntyre, A Joshi, E Abella-Dominicis, M  
Hawkins, A Reddy, J Di Paolo<sup>10</sup>, H Lee<sup>9</sup>, J He, J Hu, L Dreiling,  
J W Friedberg

**Curriculum Vitae**  
**André K. D. Liem, M.D.**

---

- Poster:International Conference on Malignant Lymphoma  
Lugano, Switzerland – June 17-20, 2015
- May 2014      Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma  
Paul M. Barr, Gene Brian Saylor, Stephen Edward Forbes Spurgeon, Bruce D. Cheson, Daniel Reif Greenwald, Susan Mary O'Brien, Andre K. D. Liem, Rosemary McIntyre, Esteban Abella-Dominicis, Michael J. Hawkins, Anita Reddy, Julie Di Paolo, Meihua Wu, Flordeliza Melchor-Khan, Feng Jin, Jonathan W. Friedberg; James P.  
J Clin Oncol 32:5s, 2014 (suppl; abstr 7059)  
ASCO MEETING ABSTRACTS 7059
- Jan 2012      Interim results of a phase II study of the mTOR inhibitor everolimus in patients with pretreated metastatic gastric and esophageal adenocarcinoma.  
Zev A. Wainberg, Ravi Patel, Brian DiCarlo, David J Park, Frederic C. Kass, Andre K. D. Liem, He-jing Wang, Diego Martinez, and J. Randolph Hecht  
ASCO MEETING ABSTRACTS Jan 30, 2012:80
- Jan 2012      Physical function and quality of life in frail and/or elderly metastatic colorectal cancer patients treated with bevacizumab and capecitabine: An exploratory analysis.  
Peter Richard Ward, Andre K. D. Liem, He-jing Wang, Ravi Patel, Eddie Hong-Lung Hu, Nerses Simon Tchekmedyan, Zev A. Wainberg, J. Randolph Hecht, and Arash Naeim  
ASCO MEETING ABSTRACTS Jan 30, 2012:627
- Jan 2010      Phase II study of frontline capecitabine (CAP)and bevacizumab (BEV) in frail and elderly patients with metastatic colorectal cancer (mCRC)  
A. Naeim, L. S. Lin, R. Dichmann, A. K. D. Liem, D. Chan, R. Patel, E. H. L. Hu, N. S. Tchekmedyan, Z. A. Wainberg, J. R. Hecht, TORI Research Team: F. Kabbinavar , H.J. Wang, and N. Ryba:  
American Society of Clinical Oncology, GI symposium Abstr. #1611
- Dec 2009      Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: a phase 1/2 study.  
Saura C, Martin M, Moroosse R, Harb W, Liem K, Arena F, Gressler V, Cortés J, Wade M, Powell C, Shapiro M  
Poster San Antonia Breast Cancer Symposium)
- June 2006      Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer  
N. S. Tchekmedyan, A. K. Liem, E. T. Quan, D. M. Burtzo, and K. Ucar  
ASCO MEETING ABSTRACTS Jun 16, 2006:15038

**Curriculum Vitae**  
**André K. D. Liem, M.D.**

---

- May 2002      Liem AK, Cheng H, Quan E, Ucar K, Al-Jazayrly G, Barton C, Cloo L, Gabert T, Tchekmedyian S: Expanded access single institution clinical program experience with ZD1839 (Iressa <sup>TM</sup>) for patients with advanced non-small cell lung cancer (NSCLC). Proc. of the American Society of Clinical Oncology, Abstr. #2705, 2002.
- Nov 2002      Tchekmedyian NS, Liem AKD: A Patient with Metastatic Non-Small-Cell Lung Cancer Treated with ZD1839. Case studies in lung cancer, a Physicians' Education Resource publication, vol.1, no. 9, November 2002.
- Jun 1989      H. J. M. Op Den Camp, K. D. Liem, P. Meesters, J. M. H. Hermans and C. Van Der Drift: Purification and characterization of the NADP-dependent glutamate dehydrogenase from *Bacillus fastidiosus*. *Antonie van Leeuwenhoek* 55:303-311 (1989)

Dr KD Liem CV 02-2017.doc